DAILY MORNING NOTE | 10 August 2022

The Straits Times Index (STI) ended Monday (Aug 8) down 0.4 per cent or 11.9 points to 3,270.98, amid a mixed regional showing. This comes after a strong US jobs data sent chills across global markets, stoking fears that another Fed rate hike may be in the works to combat inflation. Losers slightly outpaced gainers 229 to 222 in the broader Singapore market, with 1.05 billion securities worth S$941.5 million changing hands. Sembcorp Industries was the top gainer among index constituents, up 3.6 per cent or S$0.11 to S$3.18 at the closing bell. Wilmar International was at the bottom of the table, ending down 4.9 per cent or US$0.21 at US$4.09. The trio of local banks ended mixed. OCBC closed up 0.3 per cent or S$0.04 at S$12.28, DBS ended down 0.2 per cent or S$0.07 at S$32.77, while UOB lost 2.2 per cent or S$0.61 to close at S$27.20.

With all eyes on back-to-back inflation data coming this week, Wall Street stocks tumbled again on Tuesday as earnings warnings tanked tech shares. Investors may have been taking advantage of a recent upswing in share prices to cash out before the government reports on July consumer prices on Wednesday, followed by producer prices on Thursday. While the data are expected to show monthly inflation slowing from June, the annual pace is likely to remain near 40-year highs. The three major indices opened in the red and remained there throughout the trading session. The tech-rich Nasdaq Composite Index lost 1.2 per cent to finish at 12,493.93, pulled down after Micron Technologies became the second big chipmaker to warn of downbeat revenue due to ongoing global supply snarls, following a similar caution by Nvidia on Monday.

Top gainers & losers



Resorts operator Banyan Tree Group on Tuesday (Aug 9) posted a S$514,000 net profit for H1 ended June, reversing the year-ago S$42.6 million loss, as the rising tide of travel lifted all its business segments. H1 revenue more than doubled to S$118.6 million, with the hotel investments segment seeing a S$38.3 million rise in revenue to S$60.8 million as international borders reopened. Revenue for the group’s hotels in the Maldives rose by S$8.7 million from the previous year. In the fee-based segment, revenue was S$4.8 million higher due to strong performance from Banyan Tree’s managed hotels in Mexico, as well as hotel recovery in Asia. But China is an exception, as the government’s sporadic lockdowns have hit business operations, the company said in its earnings. In the next 12 months, Banyan Tree expects to open 14 new hotels and rebrand 2 hotels through conversion. Over the next 3 years, 50 new hotels are expected to open, in line with the company’s ambition to double its operating footprint.

Frasers Property has achieved pre-sold revenue of S$2.3 billion so far in FY2022 for its residential projects across Singapore, Australia, China and Thailand, the real estate group said on Monday (Aug 8) in a business update for the third quarter ended June. In Singapore, the group said the demand for quality residential developments remains resilient, with sales of launched projects strengthening despite property cooling measures introduced in December 2021. For the first 9 months of FY2022, it has sold 286 units in Singapore, with unrecognised revenue amounting to S$0.7 billion as at end June. In Australia, the group said it continued to see active management of sales and settlements amid the rising interest rate and high inflationary environment. Frasers Property in December also secured a 2.5 million square foot (sq ft) site in Queensland, which is expected to yield some 2,150 lots, as part of its strategic land banking efforts to support its development pipeline. The group added that residential properties in Thailand “remain in demand” while residential demand in China continues to stay “robust”. Meanwhile, it said its investment property portfolio is poised for recovery, with continued strong leasing activity in the industrial and logistics sector in Australia, Europe and Thailand. As borders reopen, the group said it has also increased its presence in key locations and stepped-up marketing and cross-selling activities to tap pent-up corporate stay and travel demand for its hospitality portfolio.


Pfizer has agreed to buy Global Blood Therapeutics, the maker of a drug for sickle-cell disease, in a deal worth US$5.4 billion. The New York drug giant will pay US$68.50 for all outstanding shares of Global Blood, the companies said on Monday (Aug 8) in a statement before US markets opened. That’s double the price of the stock on Aug 3, when Bloomberg reported the company was drawing takeover interest. Both boards unanimously approved the transaction. Pfizer will gain Oxbryta, South San Francisco, California-based Global Blood’s therapy for sickle-cell disease that sold about US$195 million last year and the companies see as a potential blockbuster. Pfizer needs new products as concerns about the pandemic wane, threatening revenue from its top-selling Covid-19 vaccine and its pill to treat the disease, Paxlovid. Global Blood shares rose 4 per cent in trading before US markets opened, while Pfizer’s were little changed. The Wall Street Journal reported the news earlier on Monday.

Qualcomm and GlobalFoundries signed an agreement on Monday (Aug 8) to more than double their existing long-term manufacturing agreement for chips used in 5G transceivers, Wi-Fi, automotive and Internet of Things (IoT) connectivity. Under a multi-billion dollar revenue agreement, the chips will be produced in GlobalFoundries’ factories in the United States, Germany, Singapore and France. The companies committed to support US-based manufacturing by expanding capacity at GlobalFoundries’ most advanced semiconductor manufacturing facility, in Malta, New York. US chipmaker Qualcomm was one of GlobalFoundries’ first customers to sign a long-term agreement in 2021 to cover multiple geographies and technologies. GlobalFoundries chief executive Thomas Caulfield said in a statement that having Qualcomm as a long-term customer of its upstate New York factory through 2028 would help, along with federal and state funding, to expand the company’s US manufacturing footprint. The US Senate last month passed sweeping legislation to subsidise the domestic semiconductor industry, providing about US$52 billion in government subsidies for semiconductor production and an investment tax credit for chip plants estimated to be worth $24 billion.

At an annual meeting last Thursday (Aug 4), Tesla shareholders greenlit a 3-for-1 stock split that is poised to take place on Aug 24. Essentially, shareholders will get 2 additional shares for every share of Tesla they hold on the Aug 17 record date, while trading on a split-adjusted basis will start from Aug 25. Since the electric-vehicle (EV) maker first mooted the idea of a stock split in March, the counter has outperformed the Nasdaq, surging roughly 50 per cent from a 52-week low of around US$620 in May to close at above US$925 on Aug 4. The rally came on the back of better-than-expected Q2 earnings, as well as a US$430 billion bill in the United States that is expected to deliver – among other things – EV tax credits. Tesla closed 6.6 per cent lower at US$865 on Friday (Aug 5), however, partly due to some profit-taking on the news of the confirmed share split. The counter is also below its 52-week high of over US$1,240 per share, which at the time saw its market capitalisation crossing into the trillion-dollar territory. Assuming a US$900 price, Tesla would ease to around US$300 per share after the stock split. While it doesn’t change the firm’s fundamentals, the split does increase trading liquidity and bring it more comfortably within the reach of employees and retail investors – and Tesla has certainly proved popular with retail investors in particular. The latest share split follows some 2 years after a 5-for-1 stock split in August 2020, which at the time prompted a sharp 60 per cent jump in the counter between the day it was first announced and the day it took effect.

Source: SGX Masnet, The Business Times, Bloomberg, Channel NewsAsia, Reuters, CNBC, PSR


Upcoming Webinars

Guest Presentation by A-Sonic Group

Date: 11 August 2022

Time: 12pm – 1pm

Register: https://bit.ly/3PmoIrl


Guest Presentation by Marathon Digital Holdings

Date: 18 August 2022

Time: 10am – 11am

Register: https://bit.ly/3yNSfUu


Guest Presentation by First REIT

Date: 18 August 2022

Time: 12pm – 1pm

Register: https://bit.ly/3BqQe3q


Guest Presentation by Audience Analytics

Date: 23 August 2022

Time: 12pm – 1pm

Register: https://bit.ly/3P3eBYR


Guest Presentation by Meta Health Limited (META)

Date: 24 August 2022

Time: 12pm – 1pm

Register: https://bit.ly/3nYZXWx


Guest Presentation by United Hampshire US REIT [NEW]

Date: 7 September 2022

Time: 7pm – 8pm

Register: https://bit.ly/3SgiZFV

POEMS Podcast:

Research Videos

Weekly Market Outlook: AirBnb, Apple, Amazon, DBS, OCBC, First Sponsors, Starhub, SG Weekly & More
Date: 8 August 2022
Click here for more on Market Outlook.
Sign up for our webinars here, and be among the first to receive economy and market updates.


Phillip Research in 3 minutes: #29 Keppel Corporation; Initiation
Click here for more on Phillip in 3 mins.

Follow our Socials

Facebook Social Icon Instagram Icon Twitter Social Icon Youtube Social Icon Linkedin Social Icon TikTok Social Icon Spotify Social Icon

Join our Singapore Equity Research Community on POEMS Mobile 3 App for the latest research reports, market updates, insights and more

Click to join!


The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided 揳s is?without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.

Confidentiality Note

This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you


This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  


Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com